A single arm, open-label, phase 2 study to assess the efficacy and safety of lucitanib given orally as a single agent to patients with advanced/metastatic lung cancer and FGF, VEGF, or PDGF related genetic alterations

Trial Profile

A single arm, open-label, phase 2 study to assess the efficacy and safety of lucitanib given orally as a single agent to patients with advanced/metastatic lung cancer and FGF, VEGF, or PDGF related genetic alterations

Completed
Phase of Trial: Phase II

Latest Information Update: 26 Jul 2017

At a glance

  • Drugs Lucitanib (Primary)
  • Indications Non-small cell lung cancer; Squamous cell cancer
  • Focus First in man; Therapeutic Use
  • Sponsors Clovis Oncology; EOS S.p.A.
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 10 Nov 2016 Status changed from active, no longer recruiting to completed.
    • 27 Jul 2016 Planned End Date changed from 1 Aug 2016 to 1 Oct 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top